Home2019-12-10T18:55:46+00:00

Cognitive and Movement
Disorders Affect Millions

We are rapidly advancing a pipeline of novel allosteric modulators of ion channels – taking a well-established pharmaceutical approach and stepping out into new territory. SK channels and NMDA receptors are ion channels that are critical for modulating the strength, timing, and integration of communication between and within neurons and neuronal networks in the central nervous system. But there are no approved drugs that are selective allosteric modulators of these ion channels.  Cadent’s first-of-its-kind approach has the potential to bring harmony back to neuronal rhythms, effectively “re-wiring” the brain to treat movement and cognitive disorders.

Learn More About Our Approach
Movement Disorders

Our Focus on
Movement Disorders

We are developing positive allosteric modulators (PAMs) of SK (small-conductance calcium-activated potassium) channels in the brain for the treatment of essential tremor (ET) and spinocerebellar ataxia (SCA).

Cognitive Disorders

Our Focus on
Cognitive Disorders

Our approach aims to positively modulate NMDAr, a key receptor of the most abundant neurotransmitter Glutamate, to reverse NMDAr hypofunction in people with schizophrenia and restore cognitive balance.

Learn More
Learn More
~11K

~11,000 PEOPLE AFFECTED BY
SPINOCEREBELLAR ATAXIA IN THE U.S.

5-7 MM

5-7 MILLION PEOPLE AFFECTED BY
ESSENTIAL TREMOR IN THE U.S.

~2.2MM

~2.2 MILLION PEOPLE AFFECTED BY
SCHIZOPHRENIA IN THE U.S.

Our Approach

We begin with a clear purpose: identifying a serious disease with clear unmet need. We apply novel approaches to discover new therapies and design well-controlled and powered studies to demonstrate the potential value of our medicines.

Patient
Selection

Use of genetics, translational biomarkers and other measures to carefully select patients

Patient Selection

For each disease we aim to treat, our goal is to target specific patient subsets based on genetics or other factors to identify the patients who will benefit most from treatment. In SCA, we are targeting only patients with genetically driven disease and in schizophrenia we are hoping our work in endpoint validation will lead to the development of relevant patient sub-groups that are most likely to benefit from intervention.

Target Specificity

Selection of novel, high-impact targets that can be modulated with specificity

Target Specificity

SK channels and NMDA channels are critical molecular determinants of brain circuit function, but have not been targeted with allosteric modulators for the treatment of movement or cognitive disorders. Allosteric modulation of ion channels is a proven approach to develop selective and clinically-meaningful CNS medicines. We have applied a proven medicinal chemistry approach to discover and develop positive and negative allosteric modulators of these ion channels as potential first-in-class therapeutics.

Drug Design + Optimization

Design of novel compounds to maximize benefit and minimize adverse effects

Drug Design + Optimization

We leverage our team’s significant industry experience in medicinal chemistry, target selection, drug discovery and drug optimization to rigorously evaluate our programs. Our goal is to produce candidates likely to achieve optimal efficacy with minimal side effects.

Quantitative Endpoints

Deploying novel insights to improve the precision of clinical endpoints

Quantitative Endpoints

We are working with pharmaceutical consortia and instrument companies to validate new “quantitative” endpoints that more accurately diagnose and measure disease severity than the current observation-based rating scales used by physicians. We are doing this by leveraging the best-possible measurement systems available in all of our programs.

Our Investors

News

Cadent Therapeutics to Present at the Jefferies Healthcare Conference

May 27th, 2020|

CAMBRIDGE, Mass., May 27, 2020 – Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 3, 2020 at 2:00-2:25 pm ET. The conference will be held in a virtual meeting format.

Cadent Therapeutics Closes $15 Million Final Equity Tranche of Series B Financing

April 29th, 2020|

CAMBRIDGE, Mass., April 29, 2020 – Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, today announced today that it has closed the $15 million final equity tranche of its previously announced $40 million Series B financing. The Company plans to allocate all proceeds to continue the development for its lead cognitive disorder asset, CAD-9303, a novel, first-in-class, positive allosteric modulator (PAM) of N-methyl-D-aspartate (NMDA) receptors for the treatment of the cognitive deficits and negative symptoms of schizophrenia. CAD-9303 is currently being evaluated in the Affinity-1 trial, a multicenter, randomized, placebo-controlled study. “The successful completion of our Series B financing signifies the continued support we have from our current investors and their belief in our programs,” said Jodie Morrison, Chief Executive Officer of Cadent Therapeutics. “We will be using these proceeds to advance our CAD-9303 program, which has continued to enroll patients despite the ongoing COVID-19 pandemic. This program has the potential to transform the lives of patients with schizophrenia and other cognitive deficits. With the close of this tranche, we now have sufficient cash runway into the second quarter of 2021.”

Cadent Therapeutics Announces FDA Clearance of IND Application and Dosing of Subjects of CAD-9303 for Schizophrenia

March 10th, 2020|

CAMBRIDGE, Mass., March 10, 2020 – Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that the U.S. Food and Drug Administration (FDA) has provided clearance to proceed for its Investigational New Drug (IND) application for its lead cognitive disorder asset, CAD-9303, a novel, first-in-class, positive allosteric modulator (PAM) of N-methyl-D-aspartate (NMDA) receptors for the treatment of the cognitive deficits and negative symptoms of schizophrenia. Dosing of patients is now underway in the Phase 1 clinical trial. “This IND clearance and initiation of dosing represents a critical milestone for Cadent as we progress CAD-9303 forward as the first drug candidate in our psychiatric disorders pipeline,” stated Jodie Morrison, Chief Executive Officer. “CAD-9303 serves as the first NMDA PAM to be developed to potentially transform the lives of patients with schizophrenia.”

See All Cadent News

We are developing novel allosteric modulators of ion channels to improve neuronal firing regularity. This first-of-its-kind approach has the potential to restore neuronal control and benefit patients with movement and cognitive disorders.

Contact Us to Learn More

We are developing novel allosteric modulators of ion channels to improve neuronal firing regularity. This first-of-its-kind approach has the potential to restore neuronal control and benefit patients with movement and cognitive disorders.

Contact Us to Learn More

We are developing novel allosteric modulators of ion channels to improve neuronal firing regularity. This first-of-its-kind approach has the potential to restore neuronal control and benefit patients with movement and cognitive disorders.

Contact Us to Learn More